Biodesix Launches its Liquid Biopsy Mutation Test for Lung Cancer Patients
Biodesix, Inc. has launched its targeted liquid biopsy mutation test for patients with advanced lung cancer.
Biodesix, Inc. has launched its targeted liquid biopsy mutation test for patients with advanced lung cancer.
Next time you reach into the medicine cabinet seeking relief for a headache, backache or arthritis, be aware of important safety information for non-steroidal anti-inflammatory drugs.
On July 10, the U.S. Food and Drug Administration approved Rexulti (brexpiprazole) tablets to treat adults with schizophrenia and as an add-on treatment to an antidepressant medication to treat adults with major depressive disorder (MDD).